Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass

Perfusion

Volumn 15, Issue 3, 2000, Pages 203-209

  Gruenwald, C ^a,c   De Souza, V ^a   Chan, A K C ^b   Andrew, M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CITRIC ACID; HEPARIN; PROTAMINE;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CORRELATION FUNCTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; HEMATOCRIT; HUMAN; INFANT; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MALE; NEWBORN; PEDIATRIC SURGERY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARD; STATISTICAL ANALYSIS; TITRIMETRY;

EID: 0034079544     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765910001500304     Document Type: Article

References (16)

1. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975; 69: 674-84.
2. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975; 69: 685-88.
3. Hattersley P. Activated coagulation time of whole blood. JAMA 1966; 196: 150-54.
4. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984; 63: 394-98.
5. Culliford AT, Gitel SN, Starr N et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1980; 193: 105-11.
6. Despotis GJ, Summerfield AL, Joist JH et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076-82.
7. Andrew M, MacIntyre B, Williams W et al. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemostas 1993; 70: 937-41.
8. Reich DL. Monitoring hemostasis in the perioperative period: anticoagulation control. J Cardiothorac Vase Anesth 1991; 5: 4-7.
9. Despotis GJ, Santoro SA, Spitznagel E et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994; 107: 271-79.
10. DeLaria GA, Tyner JJ, Hayes CL, Armstrong BW. Heparin-protamine mismatch. A controllable factor in bleeding after open heart surgery. Arch Surg 1994; 129: 944-50.
11. Andrew M, Paes B, Milner R, Johnston M et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70: 165-72.
12. Andrew M, Paes B, Milner R et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72: 1651-57.
13. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the haemostatic system during childhood. Blood 1992; 80: 1998-2005.
14. Gruenwald C, Andrew M, Burrows F, Williams W. Cardiopulmonary bypass in the neonate. Advances in cardiac surgery, 4th edn. St Louis, MO: Mosby-Year Book, 1993: 137-56.
15. Mann KG, Butenas S, van't Veer C. 'Normal' hemostasis [Abstract]. Blood 1998; 92.
16. Chan A, Leaker M, Burrows F et al. Coagulation profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemostas 1997; 77: 270-77.